MAP2K2 Polyclonal Antibody | E-AB-12553

MAP2K2 Polyclonal Antibody | E-AB-12553 | Gentaur UK, US & Europe Distribution

Type: Polyclonal Antibody

Synonyms: Cardiofaciocutaneous syndrome, CFC syndrome, CFC4, Dual specificity mitogen activated protein kinase kinase 2, Dual specificity mitogen-activated protein kinase kinase 2, ERK activator kinase 2, FLJ26075, MAP kinase kinase 2, map2k2, MAPK / ERK kinase 2, MAPK/ERK kinase 2, MAPKK 2, MAPKK2, MEK 2, MEK2, Microtubule associated protein kinase kinase 2, Mitogen activated protein kinase kinase 2, Mitogen activated protein kinase kinase 2 p45, MKK 2, MKK2, MP2K2, OTTHUMP00000165826, OTTHUMP00000165827, PRKMK 2, PRKMK2

Application: WB, IHC, ELISA

Reactivity: Human, Mouse, Rat

Host: Rabbit

Isotype: IgG

Reserch Areas: Cancer, Signal Transduction

Background: The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.

Concentration: 1 mg/mL

Storage: Store at -20°C. Avoid freeze / thaw cycles.

Immunogen: Synthetic peptide of human MAP2K2

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Purification Method: Affinity purification

Dilution: WB 1:1000-1:5000, IHC 1:100-1:300

Clone: N/A

Conjugation: Unconjugated

Molecular Weight(Calculated): 44 kDa

Molecular Weight(Observed): N/A